[ Inside the business ]

MRK stock analysis

MRK · Merck & Co., Inc.

Pharmaceutical preparations. Growing 5%.

Watch: a leadership change, growth that has stopped speeding up.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +5%, steady
No customer over 10%
Sales +5%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
Before running costs: 71% → 75%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −0.8%/yrDebt $53.8B
07 What could break it?2 to watch
  • Growth peaked
  • Insiders sold $39M outside pre-set plans

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth +5%, +5%, then +5% vs. a year ago. A leadership change was filed on Nov 18.

What could go wrong

Steadier than most.

It has moved 0.3× the market. In the 2008 crisis it fell 56% while the market fell 51%. Debt is moderate.

Speculative check

Not classified.

Not Self-funding because of: debt over 4× operating profit.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Growth.

It earns cash, invests heavily, and still raises money to grow.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 762¢ of each $1 of profit.

Competitive advantage

Not measurable.

Returns on capital can't be computed from its filings (common for banks and insurers).

Future bets

46% on research.

$30.8B a year on R&D. $4B on equipment and buildings.

All figures from Merck & Co., Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.